BACKGROUND: The aims of this study were to identify prognostic factors of @entity1 with @entity356 and to verify the validity of adjuvant chemotherapy for this disease. METHODS: We retrospectively examined the cases of 1,236 consecutive @entity1 in our prospectively maintained database with T1b @entity356 who underwent gastrectomy in 1995-2012. We used 11 clinicopathologic characteristics to identify prognostic factors by univariate and multivariate analyses. We compared the survival of the 160 node-positive T1b @entity356 @entity1 with that of 133 @entity1 in the same database who had node-positive muscularis @entity356 and had undergone gastrectomy without adjuvant chemotherapy during the same period, as a reference cohort. RESULTS: The 5-year overall survival rate was 91.4% for all 1,236 @entity1 . Advanced age (hazard ratio [HR] 4.51; 95% confidence interval [CI] 3.26-6.24; P  <  .01), male sex (HR 2.26; 95% CI 1.56-3.26; P  <  .01), and the presence of @entity1600 (HR 1.89; 95% CI 1.33-2.70; P  <  .01) were independent prognostic factors. The 5-year overall survival rates were 92.5% in node-negative @entity1 , 84.5% in @entity1 with 1 or 2 metastatic nodes, and 80.1% in @entity1 with 3 or more metastatic nodes (P  <  .01). The 5-year overall survival rates of the node-positive T1b and T2 @entity356 @entity1 were 83.6% and 81.2%, respectively (P  =  .73). CONCLUSION: The prognosis of node-positive T1b @entity356 @entity1 after curative gastrectomy was unsatisfactory. Adjuvant chemotherapy should be considered for these @entity1 , especially those with 3 or more metastatic nodes.

Prognostic analysis of submucosa-invasive XXXX with  @entity1600 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['lymph node metastasis'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'submucosa-invasive (T1b) gastric cancer', 'propria-invasive (T2) gastric cancer']
@entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']
